Market Intelligence, Clinical Progress, and High-Purity Reagents for DNA Damage Response (DDR) Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TP53BP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TP53BP1 Tudor Domain Recombinant Protein / Mutants High purity (>95%), Endotoxin controlled. Sequence Verified. E. coli expressed. |
View TP53BP1 Products |
| Gene Delivery | TP53BP1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and foci formation assays. |
View TP53BP1 Products |
| Benchmark Ab | Anti-TP53BP1 Recombinant Antibody Recombinant positive control for immunofluorescence and western blot. |
View TP53BP1 Products |
| Validator | TP53BP1 siRNA Set For knockdown verification in DNA damage recovery assays. |
View TP53BP1 Products |
| Related Target A | BRCA1 Critical partner in double-strand break repair pathway choice; key determinant of PARP inhibitor resistance. |
View BRCA1 Products |
| Related Target B | USP28 Deubiquitinase that stabilizes TP53BP1; emerging co-target in DDR-driven oncology. |
View USP28 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Tudor domain off-target screening | High-purity WT and mutant Tudor domain proteins strictly verified by mass spectrometry |
| Quantifying chromatin-binding disruption | Sequence-verified constructs optimized for fluorophore-conjugation and AlphaLISA |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live TP53BP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TP53BP1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small-molecule inhibitors of the Tudor domain and target-degrading PROTACs. As first-generation therapies reach the clinic, the next wave of R&D is targeting the synthetic lethal relationship between TP53BP1 inhibition and BRCA1/2-deficient tumors to overcome PARP inhibitor resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Tudor Inhibitor) | Artios Pharma, Repare Therapeutics | BRCA-mutant Ovarian & Breast Cancer | Selectivity Assay (Need Mutant vs WT Tudor Proteins) |
| PROTAC (Degrader) | Academic / Biotech Consortia | PARPi-Resistant Solid Tumors | Western Blot Validation (Need high-affinity Benchmark Abs) |
| Gene Therapy / CRISPR knockdown | DDR-focused Biotechs | Refractory Genotoxic Tumors | Functional Knockdown Validation (Need Lentivirus & siRNA) |